Gene Therapy for Hepatitis B is under clinical development by Lion TCR and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy for Hepatitis B’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy for Hepatitis B overview
Gene therapy is under development for the treatment of chronic hepatitis B virus infections. The drug candidate is developed based on T-cell receptor (TCR) therapy platform. It is administered through intravenous route.
Lion TCR overview
Lion TCR., is a clinical-stage biotechnology company that develops cell therapy for cancers and life-threatening infectious diseases. The company is headquartered in Singapore.
For a complete picture of Gene Therapy for Hepatitis B’s drug-specific PTSR and LoA scores, buy the report here.